In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017–2019

PURPOSE: Lefamulin is a novel antibiotic approved by the U.S. Food and Drug Administration in 2019 for the treatment of community-acquired bacterial pneumonia (CABP). In this study we evaluated the in vitro antimicrobial activity of lefamulin in order to better understand its antibiogram. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shi, Zheng, Yonggui, Guo, Yan, Yin, Dandan, Zhu, Demei, Hu, Fupin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525147/
https://www.ncbi.nlm.nih.gov/pubmed/33042095
http://dx.doi.org/10.3389/fmicb.2020.578824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525147/
https://www.ncbi.nlm.nih.gov/pubmed/33042095
http://dx.doi.org/10.3389/fmicb.2020.578824

Ejemplares similares